Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Table 5

Lenalidomide containing regimens in untreated indolent and mantle cell lymphoma.

Author	Year	Phase	Histology	𝑛	Age (range)	Combination	ORR (%)	CR (%)
Fowler et al. [31]	2010	II	Indolent NHL	30	56 (36–77)	RL	86	79
Samaniego et al. [32]	2011	II	Indolent NHL	75	57 (35–84)	RL	90	66
Tilly et al. [33]	2011	I	NHL	27	NR	RL-CHOP	96	74

ORR: overall response rate; CR: complete response; NR: not reported; RL: rituximab and lenalidomide; RL-CHOP: rituximab, lenalidomide, cyclophosphamide, doxorubicin, vincristine, prednisone.